Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.55% Nasdaq Up0.29%

Ampio Pharmaceuticals, Inc. (AMPE)

-NYSE MKT
5.48 Down 0.01(0.18%) Apr 15, 4:04PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Ampio Pharmaceuticals, Inc.
5445 DTC Parkway
Suite 925
Greenwood Village, CO 80111
United States - Map
Phone: 720-437-6500
Fax: 720-437-6501
Website: http://www.ampiopharma.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:16

Business Summary 

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, develops therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and decreasing vascular permeability. Its lead product candidates in development include Ampion, which is in Phase III clinical trial for osteoarthritis of the knee and Optina that is in Phase IIb clinical trial for diabetic macular edema. The company, through its subsidiaries, is also involved in the development and commercialization of RedoxSYS, an in-vitro diagnostic platform that measures human oxidation-reduction potential; and Zertane, an oral drug in late stage development as treatment for premature ejaculation in men. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Ampio Pharmaceuticals, Inc.

Corporate Governance 
Ampio Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 4; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Michael MacAluso , 63
Founder, Chairman and Chief Exec. Officer
376.00K0.00
Mr. Mark D. McGregor , 72
Chief Financial Officer, Principal Accounting Officer and Corp. Sec.
172.00K0.00
Mr. Joshua R. Disbrow , 39
Chief Operating Officer
356.00K0.00
Dr. David Bar-Or M.D. , 65
Chief Scientific Officer and Director
455.00K0.00
Mr. Richard B. Giles , 65
Director of Investor Relations, Director, Chairman of Audit Committee, Member of Nominating & Governance Committee and Member of Compensation Committee
83.00KN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders